PANOVA-4: Pilot, Single Arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06390059

Title field or adapter rule

{'original_value': 'PANOVA-4: Pilot, Single Arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:26.566433+00:00

Published At

2026-09-04T00:00:00+00:00

Record Updated At

2026-09-04

Source Retrieved At

2026-10-31T22:17:58.991924+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Metastatic Pancreatic Ductal Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-04", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06390059"

protocolSection.identificationModule.officialTitle

"PANOVA-4: Pilot, Single Arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Metastatic Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['TTFields + atezolizumab + gemcitabine and nab-paclitaxel'], 'description': 'The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the patient by means of insulated transducer arrays. The NovoTTF-200T produces TTFields that exert electric forces intended to disrupt cancer cell division.\n\nTTFields at 150 kHz application will be continuous for at least 18 hours a day on average. TTFields will be continued until disease progression according to RECISTv1.1 or loss of clinical benefit.', 'name': 'Tumor Treating Fields', 'type': 'DEVICE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['TTFields + atezolizumab + gemcitabine and nab-paclitaxel'], 'description': 'Atezolizumab is a humanized IgG1 monoclonal antibody which targets human PD-L1and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80). Both of these interactions are reported to provide inhibitory signals to T cells. Atezolizumab is administered as an intravenous solution.\n\nAtezolizumab may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.', 'name': 'Atezolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['TTFields + atezolizumab + gemcitabine and nab-paclitaxel'], 'description': 'Gemcitabine is a standard of care chemotherapy drug administered as an intravenous infusion.\n\nGemcitabine may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.', 'name': 'Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['TTFields + atezolizumab + gemcitabine and nab-paclitaxel'], 'description': 'Nab-paclitaxel is a standard of care chemotherapy drug administered as an intravenous infusion.\n\nNab-paclitaxel may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.', 'name': 'nab-paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Atezolizumab (protocolSection.armsInterventionsModule.interventions[].name)
• Gemcitabine (protocolSection.armsInterventionsModule.interventions[].name)
• nab-paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.